Distinguished in Factor 7 Deficiency

Sergio M. Siragusa

Palermo, IT 
Distinguished in Factor 7 Deficiency
Palermo, IT 
OverviewLocationsClinical Research

Overview

Sergio Siragusa practices in Palermo, Italy. Mr. Siragusa is rated as a Distinguished expert by MediFind in the treatment of Factor 7 Deficiency. His top areas of expertise are Blood Clots, Thrombocytopenia, Deep Vein Thrombosis, Thrombectomy, and Splenectomy.

His clinical research consists of co-authoring 149 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Factor 7 Deficiency.

Gender
Male

Locations

Palermo, Italy
Other Locations
Messina, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study by the Fondazione Italiana Linfomi.
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study by the Fondazione Italiana Linfomi.
Enrollment Status: Completed
Publish Date: July 16, 2025
CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)
CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Other
A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia
A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Ofatumumab
Study Phase: Phase 2
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Procedure
Study Drugs: AOP2014, Acetylsalicylic acid
Study Phase: Phase 2
ADVATE/ ADYNOVI Hemophilia A Outcome Database
ADVATE/ ADYNOVI Hemophilia A Outcome Database
Enrollment Status: Completed
Publish Date: June 17, 2024
Intervention Type: Biological
Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
Enrollment Status: Completed
Publish Date: July 21, 2022
Intervention Type: Biological
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Enrollment Status: Unknown
Publish Date: January 20, 2022
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib
Study Phase: Phase 4
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Drug
Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia
Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia
Enrollment Status: Completed
Publish Date: October 06, 2020
Intervention Type: Drug
An International Field Study for the Reliability and Validity of the Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (EORTC QLQ-CML24)
An International Field Study for the Reliability and Validity of the Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (EORTC QLQ-CML24)
Enrollment Status: Unknown
Publish Date: March 21, 2019
Clinical Practice in the Prophylaxis and Treatment of Arterial and Venous Thromboembolism in Patients With hEmatological NEoplasms and LOw PlatElets (PENELOPE Observational Study)
Clinical Practice in the Prophylaxis and Treatment of Arterial and Venous Thromboembolism in Patients With hEmatological NEoplasms and LOw PlatElets (PENELOPE Observational Study)
Enrollment Status: Completed
Publish Date: March 22, 2018
Intervention Type: Other
View 10 Less Clinical Trials

147 Total Publications

Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.
Journal: Annals of hematology
Published: March 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Siragusa's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile